Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, announced data from a preclinical study of CPI-818, its investigational small molecule T-cell signaling pathway inhibitor.

As quoted in the press release:

Study results indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity. These preclinical data are being presented in a poster titled “Biochemical, Immunologic and In Vivo Preclinical Studies with CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor That Inhibits T-Cell Receptor Signaling, Promotes Th1 Skewing, and is Efficacious in Dogs with T-Cell Lymphomas” by James W. Janc, Ph.D., Vice President of Pharmacology, Corvus Pharmaceuticals, at the 11th Annual T-cell Lymphoma Forum, which is being held January 10-12 in La Jolla, Calif.

Based on these data, Corvus plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in early 2019. The company plans to evaluate CPI-818 in a Phase 1/1b study in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and others.

Click here to read the full press release.